Adherence to a risk‐adapted screening strategy for prostate cancer: First results of the <scp>PROBASE</scp> trial-Reference-Cited by-同舟云学术

Adherence to a risk‐adapted screening strategy for prostate cancer: First results of the PROBASE trial

Published:2022-10-05 Issue:5 Volume:152 Page:854-864
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Intl Journal of Cancer

Author:

Krilaviciute Agne¹^ORCID,Albers Peter¹²^ORCID,Lakes Jale²,Radtke Jan Philipp²,Herkommer Kathleen³,Gschwend Jürgen³,Peters Inga⁴⁵,Kuczyk Markus⁴,Koerber Stefan A.⁶,Debus Jürgen⁶,Kristiansen Glen⁷,Schimmöller Lars⁸,Antoch Gerald⁸,Makowski Marcus⁹,Wacker Frank¹⁰,Schlemmer Heinz¹¹,Benner Axel¹²,Giesel Frederik¹³,Siener Roswitha⁶¹⁴,Arsov Christian²,Hadaschik Boris¹⁵,Becker Nikolaus¹^ORCID,Kaaks Rudolf¹⁶^ORCID

Affiliation:

1. Division of Personalized Early Detection of Prostate Cancer German Cancer Research Center (DKFZ) Heidelberg Germany

2. Department of Urology, University Hospital, Medical Faculty Heinrich‐Heine University Düsseldorf Germany

3. Department of Urology, Technical University of Munich School of Medicine, Klinikum rechts der Isar Munchen Germany

4. Department of Urology Medical University Hannover Hannover Germany

5. Department of Urology Krankenhaus Nordwest Frankfurt am Main Germany

6. Department of Radiation Oncology, Heidelberg University Hospital Ruprecht Karls University Heidelberg Germany

7. Institute of Pathology University Hospital Bonn Bonn Germany

8. Department of Diagnostic and Interventional Radiology, Medical Faculty Heinrich‐Heine University Düsseldorf Düsseldorf Germany

9. Institute of Diagnostic and Interventional Radiology Technical University Munich München Germany

10. Institute of Diagnostic and Interventional Radiology Medical University Hannover Hannover Germany

11. Department of Radiology German Cancer Research Center (DKFZ) Heidelberg Germany

12. Division of Biostatistics German Cancer Research Center (DKFZ) Heidelberg Germany

13. Department of Nuclear Medicine, Medical Faculty, Duesseldorf Heinrich‐Heine University Düsseldorf Düsseldorf Germany

14. Department of Urology University Hospital Bonn Bonn Germany

15. Department of Urology Heidelberg University Hospital, Ruprecht Karls University Heidelberg Germany

16. Division of Cancer Epidemiology German Cancer Research Center (DKFZ) Heidelberg Germany

Funder

Deutsche Krebshilfe

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.34295

Reference25 articles.

1. A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer

2. Prostate-specific Antigen Testing as Part of a Risk-Adapted Early Detection Strategy for Prostate Cancer: European Association of Urology Position and Recommendations for 2021

3. Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study

4. Prediction of High-grade Prostate Cancer Following Multiparametric Magnetic Resonance Imaging: Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculators

5. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prostatakarzinom-Screening? Nur evidenzbasiert, risikoadaptiert und organisiert!;Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz;2024-08-05

2. Screening for Prostate Cancer with Prostate-specific Antigen;European Urology Open Science;2024-08

3. Prostate Cancer Screening in Young Men;Journal of Personalized Medicine;2024-07-31

4. ERSPC-Studie – PSA(prostataspezifisches Antigen)-basiertes Prostatakarzinom-Screening bei älteren Patienten;Die Urologie;2024-07-18

5. Magnetic Resonance Imaging in Prostate Cancer Screening;JAMA Oncology;2024-06-01